How to Sustain Portfolio Growth Without Increasing Lifecycle Complexity

    For most pharmaceutical companies, portfolio growth is a sign of success. New products, additional indications, market expansions and licensing opportunities all contribute to business development and future revenue; however, growth also introduces a less visible challenge. As the number of products increases, so does the volume of Regulatory Affairs (RA) and Pharmacovigilance (PV) activities required to maintain them throughout their lifecycle.

    What often begins as a manageable increase in workload can gradually evolve into a complex operational environment where variations, renewals, safety reporting, labeling updates and authority interactions compete for the same internal resources. The question is no longer whether a company can support portfolio growth, but whether its Lifecycle Management model is prepared to sustain that growth efficiently.

    Portfolio Growth Affects More Than Regulatory Workload

    When discussing portfolio expansion, organizations often focus on market access, commercialization or manufacturing capacity. Yet, every additional product also generates a growing number of post-approval obligations that must be managed continuously.

    From a regulatory perspective, Marketing Authorization Holders (MAHs) are responsible for maintaining the accuracy and compliance of product information throughout the entire lifecycle of a medicinal product. This includes managing variations, renewals, commitments, labeling changes and communications with regulatory authorities. These responsibilities do not diminish after approval; in many cases, they increase as products mature and expand into new markets.

    At the same time, Pharmacovigilance activities also become more demanding. Additional products generate more safety data, more case processing activities, increased reconciliation efforts and greater complexity in signal management, periodic reporting and oversight activities. As portfolios grow, the number of interactions between Regulatory Affairs and Pharmacovigilance teams naturally increases, making coordination more critical than ever.

    The challenge is not necessarily that individual activities become more difficult; rather, the cumulative effect of multiple lifecycle activities can create significant operational pressure if processes and governance structures do not evolve at the same pace.

    When Growth Outpaces the Operating Model

    One of the most common situations observed across the industry is that portfolio growth occurs faster than organizational adaptation.

    Many companies continue operating with structures originally designed for smaller portfolios, fewer markets or lower activity volumes. Over time, this can result in duplicated work, fragmented ownership, inconsistent processes and reduced visibility over ongoing lifecycle activities.

    Highly skilled RA and PV professionals frequently find themselves spending increasing amounts of time on operational coordination rather than strategic decision-making. Submission tracking, document management, follow-up with affiliates, workload balancing and data reconciliation can gradually consume resources that were originally intended for regulatory strategy, risk management or safety oversight.

    This situation becomes particularly visible during workload peaks. A portfolio expansion may trigger multiple variations, artwork updates, safety reporting requirements and market-specific activities simultaneously. Without scalable processes and clear governance, organizations often move into a reactive mode of operation where teams focus on immediate priorities while losing visibility over the broader lifecycle landscape.

    The consequences are not limited to efficiency. Delays, inconsistencies and communication gaps can also increase compliance risks, especially when activities involve multiple stakeholders, affiliates or external partners.

    Compliance Expectations Continue to Increase

    European regulatory frameworks place significant emphasis on maintaining product quality, safety and efficacy after approval and these obligations remain applicable regardless of portfolio size.

    As a result, organizations must be able to demonstrate not only that individual activities are completed correctly, but also that they operate within a controlled and well-governed lifecycle management framework.

    This is where many companies encounter difficulties. Lifecycle activities are often managed across multiple departments, countries and systems, making it challenging to maintain consistency, traceability and oversight. As complexity grows, governance becomes just as important as execution.

    Building a Scalable Lifecycle Management Model

    Organizations that successfully sustain portfolio growth tend to share a common characteristic: they view Lifecycle Management as an integrated operational discipline rather than a collection of independent activities.

    Instead of managing Regulatory Affairs and Pharmacovigilance separately, they focus on how lifecycle activities interact across functions, products and markets. This approach helps improve visibility, reduce duplication and strengthen coordination between teams.

    Growth Should Not Create Operational Instability

    Portfolio growth will continue to be a strategic priority for pharmaceutical companies, particularly as organizations seek new opportunities through licensing agreements, acquisitions and international expansion. The challenge is ensuring that lifecycle operations evolve alongside that growth.

    A scalable Lifecycle Management approach allows organizations to maintain control over regulatory and pharmacovigilance activities, improve operational efficiency and preserve compliance standards without continuously increasing internal complexity.

    Ultimately, the most successful companies are not those that avoid complexity, but those that develop the capabilities, processes and governance needed to manage it effectively. As portfolios continue to expand, Lifecycle Management becomes less about handling individual activities and more about building an operating model capable of supporting sustainable growth over the long term.

    Looking for Support with Lifecycle Management?

    At QbD Group, we support pharmaceutical and biotech companies in building scalable Regulatory Affairs and Pharmacovigilance processes, governance frameworks, and lifecycle operations aligned with evolving regulatory expectations.

    Want to discuss how to manage your growing portfolio without increasing operational complexity? Talk to our experts and build the right Lifecycle Management model from the start.

    Sources

    • European Medicines Agency (EMA). Guideline on the details of the various categories of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products.
    • European Medicines Agency (EMA). Good Pharmacovigilance Practices (GVP) Modules.
    • European Commission. Directive 2001/83/EC on the Community code relating to medicinal products for human use.
    • International Council for Harmonisation (ICH). ICH E2E Pharmacovigilance Planning.
    • International Council for Harmonisation (ICH). ICH Q10 Pharmaceutical Quality System.